Sameem M Abedin MD

Hematologic Oncology

Associate Professor

Summary

Sameem Abedin, MD, is an oncologist with a subspecialty in Hematologic Oncology, located in Milwaukee, WI. He completed his fellowship at the McGaw Medical Center of Northwestern University and has previously worked as a Fellow at Northwestern Memorial Hospital and as an Attending Physician at the University of Michigan Medical Center. His familiarity spans across hematologic oncology, bone marrow transplantation, and leukemia. He has several publications to his name and has contributed to clinical trials related to Acute Myeloid Leukemia, Acute Graft Versus Host Disease, and high-risk myelodysplastic syndrome.

McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2014 - 2017
UPMC Medical EducationResidency, Internal Medicine, 2009 - 2012
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2009

PubMed

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.
Zachariah DeFilipp, Haesook T Kim, Laura W Knight, Suzanne M O'Connor, Shilton E Dhaver
Blood. 2025-03-19
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.
Matthew S Davids, Danielle M Brander, Yesid Alvarado-Valero, Catherine S Diefenbach, Daniel N Egan
Blood Advances. 2025-02-25
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.
Sameem M Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, Laura C Michaelis, Karen-Sue Carlson
Leukemia. 2025-02-15

Abstracts/Posters

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...
Sameem Abedin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)
Sameem Abedin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Actimab-a Trial Shows Promise for High-Risk AML PatientsMarch 17th, 2025
$Actinium Pharmaceuticals Announces Publication of Actimab-a + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia$
Actinium Pharmaceuticals Announces Publication of Actimab-a + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal LeukemiaMarch 17th, 2025
$Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-a CLAG-M Combination Trial Oral Presentation at ASH$
Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-a CLAG-M Combination Trial Oral Presentation at ASHDecember 12th, 2022
Join now to see all